Navigation Links
Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
Date:2/11/2008

LAVAL, QC, Feb. 11 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces today that on Wednesday, February 13, 2008, Dr. Francesco Bellini, Neurochem's Chairman, President and Chief Executive Officer, and Mr. Gary Schmid, Chief Executive Officer of the new nutraceutical business, will present Neurochem's strategy at the 2008 BIO CEO & Investor Conference to be held at the Waldorf-Astoria, in New York (NY). The presentation will take place at 11:00 A.M. EST, in the West Foyer room.

The live Web cast of Neurochem's presentation (audio and visual) can be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NRMX&item_id=17. A replay of the presentation will begin one (1) hour after the actual presentation time, and will be available until February 20, 2008. Please access the Web cast approximately 15 minutes before the presentation is scheduled to begin.

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.

For further information, please contact:

Lise Hebert, PhD,

Vice President, Corporate Communications

Tel: (450) 680-4572

lhebert@neurochem.com


'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
2. Neurochem to present at JPMorgan Healthcare Conference
3. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
4. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
5. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
6. Neurochem reports results for third quarter of fiscal 2007
7. U.S. Representatives Urge Critical Improvements in Prostate Cancer Detection
8. Covance to Present at UBS Global Healthcare Services Conference
9. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
10. Mark Wylie and Suzy Preston Hoover Bring The Biggest Loser Million Pound Tour, Presented by MSN, to Dadeland Mall
11. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... NCPDP announced ... on Tuesday with Frank Luntz, sharing a dynamic, bi-partisan environmental scan of healthcare-related ... dive on NCPDP’s model solution to help stem the tide of the opioid ...
(Date:5/4/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – is set to return to the esteemed Quaker Ridge Golf Club in ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... The ... Day to recognize chaplains for their valuable support to patients and their families, and ... May 10. , To mark Spiritual Care Day, SCA has sent “Thank You Chaplain” ...
(Date:5/4/2016)... Charles, LA (PRWEB) , ... May 04, 2016 , ... ... Charles, LA area has teamed up with Big Brothers Big Sisters of Southwest Louisiana ... now being accepted here . , Big Brothers Big Sisters of Southwest Louisiana ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... SS&A teamed up with one of the top website design companies to create ... informative legal articles related to the law firm's main practice areas. These practice ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 BiondVax Pharmaceuticals Ltd. ... Ron Babecoff , will be attending the Joseph Gunnar ... . On Thursday, May 5, Dr. Babecoff will ... by Joseph Gunner & Co, taking place at ... that Dr. Babecoff will be using is downloadable from BiondVax,s ...
(Date:5/4/2016)... Jersey , May 4, 2016 ... successful completion of an alternative public offering (APO). This ... owned operating company, Valeritas, Inc. and a private placement ... stock at $5.00 per share. Under the ... May 3, 2016, Valeritas Holdings, Inc. will trade on ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
Breaking Medicine Technology: